RYAH Group, Inc.
RYAHF
Other OTC0.01
USD
- -
- -
RYAH Group, Inc.
RYAHF
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- RYAH Group, Inc. is a technology company specializing in the development and commercialization of personalized wellness ecosystems for the medical cannabis industry and other plant-based medicines using IoT-connected medical devices, AI analytics, and big data. The company offers core products including the RYAH Smart Inhaler, a volumetric airflow sensor-enabled device that tracks and controls inhalation; the RYAH Smart Patch, which allows users to boost their patch for on-demand relief; and the RYAH MD platform, designed for health practitioners to remotely monitor and manage patients' vaporization and patch regimens. These products combine to deliver precise dosing and real-time data analytics aimed at optimizing therapeutic outcomes. Founded in 2016 and headquartered in Brooklyn, New York, RYAH operates primarily in the United States with international reach. Recently, RYAH Group completed a reverse takeover with Potbotics Inc., expanding its technology and product offerings within the plant-based medical industry. The company has secured multiple medical device certifications including Health Canada licensing for its Smart Inhaler system, underscoring its commitment to compliance and regulatory approval. Furthermore, RYAH entered into strategic partnerships to advance clinical research applications of its IoT ecosystem, including an agreement with OMNI to enable controlled cannabis dosing experience and to support FDA approval efforts for clinical studies. The company continues to focus on integrating big data and AI to enhance predictive analytics for plant-based medicine efficacy, positioning itself uniquely in the digital health and medical cannabis technology sectors. These developments mark a clear strategic focus on expanding its medical device portfolio and fostering partnerships to drive adoption in healthcare settings.